| 28th Jan 2022 7:00 am |
RNS |
Grant of options |
| 24th Jan 2022 7:00 am |
RNS |
Faron at Proactive One2One Investor Forum |
| 17th Jan 2022 7:00 am |
RNS |
Faron to Present at Redeye Fight Cancer Seminar |
| 5th Jan 2022 7:00 am |
RNS |
Faron to Present at H.C. Wainwright BioConnect |
| 4th Jan 2022 7:00 am |
RNS |
Faron Appoints Marie-Louise Fjällskog as CMO |
| 21st Dec 2021 7:00 am |
RNS |
Faron’s financial calendar for 2022 |
| 9th Dec 2021 7:00 am |
RNS |
Faron Announces Topline MATINS Biomarker Analysis |
| 1st Dec 2021 7:00 am |
RNS |
Change in Faron’s Management Team |
| 16th Nov 2021 7:00 am |
RNS |
Faron to Present at Jefferies Conference 2021 |
| 9th Nov 2021 7:00 am |
RNS |
Faron awarded EUR 3.8 Million in Arbitration Case |
| 3rd Nov 2021 3:55 pm |
RNS |
Cellular and Molecular Life Sciences Publication |
| 7th Oct 2021 7:00 am |
RNS |
Exercise of options |
| 5th Oct 2021 11:30 am |
RNS |
Holding(s) in Company |
| 1st Oct 2021 2:00 pm |
RNS |
Registration of Placing Shares with Trade Register |
| 1st Oct 2021 7:00 am |
RNS |
Results of Placing and Issue Price |
| 30th Sep 2021 4:31 pm |
RNS |
Proposed Issue and Placing of Shares |
| 17th Sep 2021 7:00 am |
RNS |
Presentation of Updated MATINS Data at ESMO |
| 9th Sep 2021 7:00 am |
RNS |
Faron Announces Presentation at ESMO Congress |
| 7th Sep 2021 7:00 am |
RNS |
Faron to Present at H.C. Wainwright Conference |
| 26th Aug 2021 7:00 am |
RNS |
Half-Year Financials, January 1 – June 30 2021 |
| 25th Aug 2021 7:00 am |
RNS |
First Patient Dosed in Phase II/III COVID-19 Trial |
| 28th Jul 2021 7:00 am |
RNS |
Notice of Half-Year Report |
| 12th Jul 2021 7:00 am |
RNS |
Faron to Host KOL Webinar on Clever-1 Receptor |
| 22nd Jun 2021 7:00 am |
RNS |
Updated corporate presentation |
| 14th Jun 2021 11:05 am |
RNS |
Second Price Monitoring Extn |
| 14th Jun 2021 11:00 am |
RNS |
Price Monitoring Extension |
| 14th Jun 2021 7:00 am |
RNS |
Bexmarilimab granted key US patent |
| 3rd Jun 2021 7:00 am |
RNS |
Bexmarilimab results published in CCR |
| 17th May 2021 7:00 am |
RNS |
Bexmarilimab shows promising anti-tumour activity |
| 14th May 2021 7:00 am |
RNS |
US rights to patent related to Traumakine |
| 10th May 2021 2:30 pm |
RNS |
Holding(s) in Company |
| 29th Apr 2021 12:45 pm |
RNS |
Grant of options |
| 23rd Apr 2021 1:45 pm |
RNS |
Board Change |
| 23rd Apr 2021 1:45 pm |
RNS |
Result of AGM |
| 29th Mar 2021 7:00 am |
RNS |
Appointment of a Broker |
| 25th Mar 2021 7:45 am |
RNS |
Exercise of Options |
| 25th Mar 2021 7:30 am |
RNS |
Notice of Faron Pharmaceuticals Ltd’s AGM |
| 25th Mar 2021 7:15 am |
RNS |
Faron´s Annual Report 2020 published |
| 25th Mar 2021 7:00 am |
RNS |
Financial statement January 1 to December 31 2020 |
| 22nd Mar 2021 7:00 am |
RNS |
Bexmarilimab (Clevegen) development update |
